289 patents
Page 13 of 15
Utility
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
1 Jun 20
Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof.
Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
Filed: 18 Nov 18
Utility
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
1 Jun 20
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
Filed: 29 Jul 18
Utility
Antiproliferative Compounds and Methods of Use Thereof
27 May 20
Compounds of formula I for treating, preventing or managing cancer are disclosed.
Brian E. Cathers, Matthew Daniel Correa, Joshua Hansen, Ehab M. Khalil, Antonia Lopez-Girona, Kyle MacBeth, Hon-Wah Man, George W. Muller, Michael Pourdehnad, Raj Raheja
Filed: 9 Jun 19
Utility
Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
18 May 20
Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
Filed: 10 Dec 19
Utility
Combination therapy for treating malignancies
18 May 20
Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.
Samuel V. Agresta, Krishnan Viswanadhan, Jorge DiMartino, Vivek Saroj Kumar Chopra, Kyle J. MacBeth, Robert Douglas Knight, Laurie Kenvin, Qiang Xu
Filed: 13 Oct 16
Utility
Isotopologues of 5-azacytidine
11 May 20
The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach.
John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
Filed: 24 Sep 19
Utility
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
11 May 20
Ellen Filvaroff, Antonia Lopez-Girona, Gang Lu
Filed: 5 Jan 17
Utility
Crystalline 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE Hemihydrate, Compositions and Methods of Use Thereof
6 May 20
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate.
Jerry Lee Atwood
Filed: 30 Oct 19
Utility
Crystalline 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE Dihydrate, Compositions and Methods of Use Thereof
29 Apr 20
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate.
Jerry Lee Atwood
Filed: 30 Oct 19
Utility
Treatment of Hepatocellular Carcinoma Characterized by Hepatitis B Virus Infection
22 Apr 20
Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
Ellen FILVAROFF, Kristen M. HEGE, Shaoyi LI
Filed: 20 Jun 18
Utility
Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
20 Apr 20
Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.
Ying Li, Hon-Wah Man
Filed: 10 Dec 18
Utility
Compositions and Methods of Use of CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H-PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE
15 Apr 20
Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
Filed: 10 Dec 19
Utility
Methods of Classifying Diffuse Large B-cell Lymphoma
15 Apr 20
A method of predicting if a subject has an Activated B Cell-like (ABC) subtype or a non-ABC subtype of Diffuse Large B-Cell Lymphoma (DLBCL), comprising (a) obtaining a sample from the subject; (b) measuring the expression levels of CD10, MUM1, FOXP1, and optionally Bcl-6; (c) determining a composite score based on the expression levels of CD10, MUM1, and FOXP1, and optionally Bcl-6; and (d) predicting if the subject has an ABC subtype or a non-ABC subtype of DLBCL based on the composite score.
Yixin WANG, Sarah HERSEY, Fadi George TOWFIC, Alberto RISUENO PEREZ
Filed: 8 Oct 19
Utility
Antiproliferative compounds, and their pharmaceutical compositions and uses
13 Apr 20
Compounds of formula A-I and B-I, compositions comprising the compounds, methods of making the compounds and methods of their uses are disclosed.
Matthew D. Alexander, Matthew D. Correa, Joshua Hansen, Raj Kumar Raheja, John Sapienza
Filed: 21 Jan 19
Utility
Combination Therapy for the Treatment of Cancer
1 Apr 20
Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab.
Michael D. Amatangelo, Chad Bjorklund, Anjan Thakurta, Xiankang Hong, Mariana Cota
Filed: 29 Sep 19
Utility
Isotopologues of 5-AZACYTIDINE
1 Apr 20
The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach.
John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
Filed: 24 Sep 19
Utility
Vitro Cell Culture Methods for Beta-thalassemia Using Activin Type II Receptor Ligand Traps
1 Apr 20
Provided herein are methods of treating beta-thalassemia in a subject comprising administering to the subject an activin type II receptor (ActRII) signaling inhibitor (e.g., an activin ligand trap) and utilizing one or more in vitro cell culture methods provided herein in (i) selection of the subject to be treated according to the methods provided herein; and/or (ii) monitoring of the subject being treated according to the methods provided herein.
Maria CAPPELLINI, Victoria SUNG
Filed: 10 Dec 19
Utility
SIRP-Alpha BINDING PROTEINS AND METHODS OF USE THEREOF
1 Apr 20
Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-α (SIRPα) and modulate the activity of SIRPα.
Mahan Abbasian, Henry H. Chan, Laure Escoubet, Gustavo Fenalti, Kandasamy Hariharan, Monica Wai Ling Leung, Konstantinos Mavrommatis, David P. Mikolon, Heather K. Raymon, Carlo Steven Santos, Jeonghoon Sun, Christina Valerie Trout
Filed: 24 Sep 19
Utility
Methods for Treating Myeloproliferative Neoplasm-associated Myelofibrosis and Anemia
1 Apr 20
Provided herein are methods for treating myeloproliferative neoplasm-associated myelofibrosis in a subject, comprising administering to the subject an ActRIIB signaling inhibitor.
Abderrahmane Laadem, Robert Gale
Filed: 12 Jun 18
Utility
Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof
30 Mar 20
Provided herein are compositions including the crystalline forms of (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide (“Compound A”), methods of making the crystalline forms, and methods of using the crystalline forms for the treatment of diseases, including, for example, cancer.
Hon-Wah Man, Timothy D. Fitzpatrick, Anthony Frank, Ying Li, Xiaoling Lu, Marie G. Beauchamps, Antonio C. Ferretti
Filed: 12 Sep 19